AI-generated · cited to primary sources · not investment advice · How we research
Sai Life
Our verdict on Sai Life isn’t the consensus take — see where we landed, and the one risk the bull case glosses over.
See the verdict — free →Does management do what it says?
The company achieved an EBITDA margin of 34% in Q3 FY26 and 30% for 9M FY26, reaching the upper end of their long-term goal ahead of schedule. (4 exceeded, 1 met across 5 tracked commitments)
“Invested ₹405 Cr as on date in capital expenditure, against a plan of ₹700 Cr for FY26”
The expansion to 1,150 KL is underway with specific blocks (PB 14 & 15) scheduled for 2026 completion. (1 in progress across 1 tracked commitment)
“These strategic investments will nearly double Sai’s overall manufacturing capacity by FY27, while diversifying its footprint and reducing concentration risk”
The company reports current digitization levels at 85% and maintains the 2027 completion timeline. (1 in progress across 1 tracked commitment)
“Digitization process in manufacturing expected to be complete by CY 2027”
Targeting completion of the new CMC Process R&D Center by September 2026. — target: Completion (+1 more commitment)
“Sai Life Sciences has commenced construction of a new CMC Process R&D Center at its Hyderabad campus, targeted for completion by September 2026. The facility will double Process R&D capacity.”
The company is expanding Bidar capacity from 700 KL to 1,150 KL, with 225 KL expected to come online in FY27. — target: 1,150 KL total (225 KL in FY27)
“we've started the 700 KL to 1,150 KL capacity expansion sometime during middle of last year, we're expecting 225 KL to come this year and 225 KL next year.”
See the full cited Management analysis of Sai Life
How durable is the business?
The CDMO segment is expanding rapidly, with revenue more than doubling year-on-year, driven by deeper engagement with global clients and increased manufacturing capacity. (5 expanding)
“CDMO recorded revenues of ₹314 Cr in Q1FY26, up 113% from ₹148 Cr in Q1FY25”
The moat is strengthening as the company doubles its Process R&D capacity and expands into new modalities like peptides and ADCs, deepening the 'integrated' nature of their client partnerships. (2 expanding)
“No, actually, research is doubling. And we are adding, obviously, formulation services, early phase formulation, peptide capability in the research building... that forward-looking approach has given us that little bit of an edge.”
The company is deepening its geographic moat by becoming a strategic 'India footprint' for global pharma, specifically targeting the top 25 global pharma companies. (1 expanding)
“300+ Active customers across US, UK, EU, Japan”
The moat is expanding through 'integrated' discovery programs where clients use multiple services, making them stickier. Over 65% of discovery programs are now integrated. (5 expanding across 2 engines)
“The CRO and the CDMO business for the year demonstrated a healthy growth rate, 24% for CRO and 33% for the CDMO business.”
The company's regulatory moat remains strong and stable, completing 38 total audits in the last 12 months with zero critical observations, reinforcing its status as a trusted partner. (3 stable)
“USFDA, PMDA: 100% successful track record of regulatory inspections across our R&D and manufacturing facilities.”
See the full cited Business Model analysis of Sai Life
Where does growth come from?
The company is aggressively accelerating its capital expenditure, investing ₹134 Cr in Q1FY26 alone with a planned annual spend of ~₹700 Cr for FY26 to nearly double manufacturing capacity by FY27. (5 accelerating across 5 signals, 3 leading indicators)
“Positioned to achieve 15-20% revenue CAGR over 3-5 years* & 28-30% EBITDA margins in the next 2-3 years*”
CDMO revenue growth is accelerating significantly, jumping from 33% YoY in previous periods to 113% YoY in the current quarter. (5 accelerating across 5 signals)
“CDMO recorded revenues of ₹1,417 Cr in FY26, up 33% from ₹1068 Cr in FY25”
Revenue from complex new modalities (Peptides, ADCs) is accelerating, increasing its share of total revenue from 3% in FY24 to 7% in FY25. (3 accelerating, 1 decelerating, 1 new trend across 5 signals, 1 leading indicator)
“At the same time, we are investing in next-generation technologies, particularly in ADCs, where we are seeing significant interest and program inflow from large pharma.”
The company has a growing pipeline of products moving toward mass production, including 34 molecules already being sold commercially and 11 in the final stages of testing. — Commercial and Phase III Molecules: Added 4 commercial and 5 Phase III molecules recently
“We continue to build a strong pipeline of commercial molecules with the tally standing at 34 commercial molecules, 11 in Phase III pre-registration, and about 155 in earlier stages of development.”
The company is maintaining a heavy investment cycle, with H1 FY26 capex already at ₹248 crores against a full-year plan of ₹700 crores, indicating a steady execution of infrastructure build-out. (1 steady, 1 accelerating across 2 signals)
“We incurred a capex of around INR 248 crores for the first half, against a plan of INR700 crores for the entire FY26.”
See the full cited Future Growth analysis of Sai Life
What could break the thesis?
Execution risk is intensifying as the company has multiple large-scale projects running simultaneously, including a new 200 KL capacity at Bidar and a new Process R&D Block in Hyderabad. Managing the 'onboarding of 253 scientists' and technical staff while commissioning these sites increases the complexity of execution. (5 intensifying, 2 high-severity)
“For fiscal '27, we expect capex in the range of INR1,100 crores to 1,300 crores... We expect to fund the capex through a mix of internal accruals and debt.”
This risk is emerging as a more concrete concern due to geopolitical discussions regarding 'most favored nation' policies and US reshoring. However, management believes R&D will remain in Asia and the impact on intermediates will be minimal. (1 emerging, 2 easing, 1 intensifying)
“it's almost impossible right now to figure out the geopolitical angle... the geographies we supply to might change and how tariff is affected.”
The risk remains high as the company continues its aggressive expansion, investing ₹134 Cr in Q1FY26 alone. While revenue is growing, the heavy front-loaded spending on new R&D and manufacturing blocks (like the new Process R&D Block in Hyderabad) continues to put pressure on the balance sheet before these assets become fully productive. (2 stable, 1 easing, 1 intensifying)
“During the quarter, we invested ₹134 Cr in capex. This includes investments in new R&D infrastructure and process development capabilities... we are focused on scaling execution, strengthening client partnerships, and investing in technology.”
This risk appears to be easing. Despite macroeconomic uncertainty, the company achieved a 305% YoY growth in EBITDA and expanded margins to 25%. This suggests they are successfully managing costs through 'operating leverage' and 'improved productivity across sites.' (2 easing)
“We recorded EBITDA of ₹125 Cr, growing 305% YoY, with margins expanding to 25%... driven by operating leverage, scale efficiencies, and improved productivity.”
The risk is EASING as the company is successfully diversifying its client base. They now report 300+ active customers, including 18 of the top 25 global pharma companies, and are expanding into new modalities to attract a broader range of clients. (2 easing, 1 stable)
“300+ Active customers across US, UK, EU, Japan... 18/25 of the largest pharmaceutical companies are customers”
See the full cited Risk analysis of Sai Life
Read the full thesis on Sai Life
AI-generated informational research only. ThesisLoop is not investment advice, a stock recommendation, or a guarantee of returns.